The sensitivity to PGI2 of platelets of 20 selected type IIa hypercholesterolemic patients was studied and compared to that of platelets of 14 normocholesterolemic subjects. Type IIa subjects required higher concentrations of PGI2 to inhibit platelet aggregation elicited by 1 microM ADP, 1 microgram/ml collagen and 1.4 microM epinephrine. Adenylate cyclase activity was also measured in washed platelet membranes from the two groups of subjects. Adenylate cyclase activity, both basal and PGI2-stimulated, was not statistically different in the two groups examined. Therefore changes at the level of PGI2 receptors coupled to adenylate cyclase are not likely to be responsible for the different platelet sensitivity to prostacyclin
Activated human platelets synthesize prostaglandin (PG) E(2), although at lower rate than thromboxan...
Thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) may aggregate platelets via a common membrane rece...
Variability in integrity of platelet prostanoid adenylate cyclase signaling: pathogenetic and therap...
Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on ...
The effect of five thromboxane-synthase inhibitors (UK-37248, UK-38485, UK-34787, CGS-1 3080 and OKY...
Platelet aggregation induced by collagen, ADP and epinephrine, was monitored in 150 type-II patients...
in platelets at concentrations which could inhibit ag-gregation via activation of adenylate cyclase....
A novel chemical synthesis of nat- and rac-Prostacyclin (PGI2) and 5,6-dihydro-PGI2 is described. Li...
Prostacyclin (PGI2), an unstable endogenous prostanoid, is a potent vasodilator and inhibitor of pla...
SUMMARY Platelets provide an accessible and homogeneous cellular system for investigative stud-ies o...
The in vitro effects of ZK 36 374, a new chemically stable prostacyclin (PGI2) analog, on platelet a...
Platelet-rich plasma was obtained from patients with untreated heterozygous familial hypercholestero...
Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) ...
Activated human platelets synthesize prostaglandin (PG) E(2), although at lower rate than thromboxan...
Activation and inhibition of adenylate cyclase in purified human platelet membranes by hormones and ...
Activated human platelets synthesize prostaglandin (PG) E(2), although at lower rate than thromboxan...
Thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) may aggregate platelets via a common membrane rece...
Variability in integrity of platelet prostanoid adenylate cyclase signaling: pathogenetic and therap...
Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on ...
The effect of five thromboxane-synthase inhibitors (UK-37248, UK-38485, UK-34787, CGS-1 3080 and OKY...
Platelet aggregation induced by collagen, ADP and epinephrine, was monitored in 150 type-II patients...
in platelets at concentrations which could inhibit ag-gregation via activation of adenylate cyclase....
A novel chemical synthesis of nat- and rac-Prostacyclin (PGI2) and 5,6-dihydro-PGI2 is described. Li...
Prostacyclin (PGI2), an unstable endogenous prostanoid, is a potent vasodilator and inhibitor of pla...
SUMMARY Platelets provide an accessible and homogeneous cellular system for investigative stud-ies o...
The in vitro effects of ZK 36 374, a new chemically stable prostacyclin (PGI2) analog, on platelet a...
Platelet-rich plasma was obtained from patients with untreated heterozygous familial hypercholestero...
Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) ...
Activated human platelets synthesize prostaglandin (PG) E(2), although at lower rate than thromboxan...
Activation and inhibition of adenylate cyclase in purified human platelet membranes by hormones and ...
Activated human platelets synthesize prostaglandin (PG) E(2), although at lower rate than thromboxan...
Thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) may aggregate platelets via a common membrane rece...
Variability in integrity of platelet prostanoid adenylate cyclase signaling: pathogenetic and therap...